Mahshid Rahmat,Kendell Clement,Jean-Baptiste Alberge,Romanos Sklavenitis-Pistofidis,Rohan Kodgule,Charles P. Fulco,Daniel Heilpern-Mallory,Katarina Nilsson,David Dorfman,Jesse M. Engreitz,Gad Getz,Luca Pinello,Russell Ryan,Irene M. Ghobrial

Abstract:MYC deregulation occurs in the majority of multiple myeloma (MM) cases and is associated with progression and worse prognosis. Enhanced MYC expression occurs in about 70% of MM patients, but it is known to be driven by translocation or amplification events in only ~40% of myelomas. Here, we used CRISPR interference (CRISPRi) to uncover an epigenetic mechanism of MYC regulation whereby increased accessibility of a plasma cell-type specific enhancer leads to increased MYC expression. This native enhancer activity was not associated with enhancer hijacking events but led to specific binding of c-MAF, IRF4, and SPIB transcription factors that activated MYC expression in the absence of known genetic aberrations. In addition, focal amplification was another mechanism of activation of this enhancer in approximately 3.4% of MM patients. Together, these findings define an epigenetic mechanism of MYC deregulation in MM beyond known translocations or amplifications and point to the importance of non-coding regulatory elements and their associated transcription factor networks as drivers of MM progression.

Selective Enhancer Gain of Function Deregulates MYC Expression in Multiple Myeloma